A Phase II Study of Thymoglobulin in Patients With Multiple Myeloma Who Are Candidates for Allogeneic or Autologous Stem Cell Transplant
- Determine the response rate at 4 weeks in patients with multiple myeloma treated with
anti-thymocyte globulin at least 4 to 6 weeks prior to undergoing conditioning therapy
for allogeneic or autologous stem cell transplantation.
- Determine the toxicity of this drug, in terms of formation of antirabbit antibodies, in
OUTLINE: This is an open-label, multicenter study.
Patients receive anti-thymocyte globulin IV over 6 hours on day 1 and over 4 hours on days 3
and 5. Treatment begins 4 to 6 weeks prior to undergoing conditioning therapy for autologous
or allogeneic stem cell transplantation.
After completion of study treatment, patients are followed at 28 days.
PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Response rate, as measured by International Bone Marrow Transplant Registry (IBMTR)/European Group for Blood and Marrow Transplantation (EBMT) Response Criteria, at 4 weeks
William I. Bensinger, MD
Fred Hutchinson Cancer Research Center
United States: Federal Government
|Fred Hutchinson Cancer Research Center||Seattle, Washington 98109|